Colorectal Cancer

Quantitative vessel tortuosity features were able to detect the VEGFR inhibitory mechanism of fruquintinib in metastatic colorectal cancer.

A survey of UK and German physicians found that OS gains were needed to accept increased toxicities or treatment burden with third-line regimens in mCRC.

Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.

A post hoc subgroup analysis of FRESCO-2 shed light on the safety and efficacy of fruquintinib by metastatic site in metastatic colorectal cancer.

CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.

Drs Park and Malla discuss therapeutic options for patients with metastatic colorectal cancer, particularly in the third-line setting and beyond.

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

Zanzalintinib plus atezolizumab improved overall survival in previously treated, non–MSI-H metastatic colorectal cancer.

Jessica Paulus, ScD, highlights factors that may contribute to the increasing incidence of colorectal cancer in patients younger than 50 years of age.

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS; and Katrina S. Pedersen, MD, discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for microsatellite instability-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

The NCCN has added the Shield blood test and the ColoSense test to its colorectal cancer screening guidelines.

Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.

Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.

MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.

Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.

Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.

John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.

S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.